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Abstract: The ischemic disorders, in which platelet aggregation and blood coagulation are 
involved, represent a major cause of disability and death worldwide. The antithrombotic 
therapy has unsatisfactory performance and may produce side effects. So, there is a need to 
seek molecules with antithrombotic properties. Marine organisms produce substances with 
different well defined ecological functions. Moreover, some of these molecules also exhibit 
pharmacological  properties  such  as  antiviral,  anticancer,  antiophidic  and  anticoagulant 
properties. The aim of this study was to evaluate, through in vitro tests, the effect of two 
extracts of brown algae and ten marine sponges from Brazil on platelet aggregation and 
blood coagulation. Our results revealed that most of the extracts were capable of inhibiting 
platelet  aggregation  and  clotting  measured  by  plasma  recalcification  tests,  prothrombin 
time,  activated  partial  thromboplastin  time,  and  fibrinogenolytic  activity.  On  the  other 
hand,  five  of  ten  species  of  sponges  induced  platelet  aggregation.  Thus,  the  marine 
organisms  studied  here  may  have  molecules  with  antithrombotic  properties,  presenting 
biotechnological potential to antithrombotic therapy. Further chemical investigation should 
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be conducted on the active species to discover useful molecules for the development of 
new drugs to treat clotting disorders. 
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1. Introduction 
Hemostasis is a physiological process that involves platelet aggregation and blood coagulation. The 
coagulation system is divided into initiation and augmentation phases, and both lead to generation  
of  thrombin,  that  is  the  pivotal  enzyme  responsible  for  formation  of  a  fibrin  net  that  prevents 
hemorrhage [1]. Platelets are equally important to form thrombus. After their activation by agonists 
(collagen,  adenosine  diphosphate  (ADP)  or  thrombin),  they  contribute  by  amplifying  the  blood 
coagulation system [2]. If uncontrolled, coagulation may produce vascular disturbs, such as venous 
thromboembolism,  cardiovascular  disturbs  or  pulmonary  embolism.  These  pathologies  in  fact, 
contribute  to  increases  in  mortality  and  morbidity  in  the  world  and  have  become  a  public  health 
problem [3]. Actually, they represent the main cause of death, even more than cancer [4]. Therefore, 
safe and more efficient anticoagulants should be designed or discovered. In literature and in practice, a 
variety of drugs for managing thrombotic disorders have been used, including vitamin K antagonists, 
direct thrombin inhibitors, oral anticoagulants (apixaban, dabigatran and rivaroxaban), and recently a 
pentasaccharide. Heparin and warfarin are among the drugs associated with serious medication errors 
and are also considered as high-alert medications [5,6]. Antiplatelet drugs are also given to yield the 
greatest benefits, mainly to those patients at high thrombotic risk. These drugs may interfere with 
platelet adhesion, aggregation or activation, thus controlling the role of platelets in amplifying the 
thrombotic process [7]. Although these therapies have proven benefits, they have important limitations 
and may produce side effects, such as bleeding, thrombocytopenia, gastric disorders, narrow therapeutic 
index and window, drug or dietary interactions as well as sometimes requiring monitoring [3,8]. In 
fact,  antithrombotic  therapies  may  induce  mild  or  even  more  severe  symptoms.  Because  of  this, 
researchers  are  looking  for  molecules  with  satisfactory  antiplatelet  and/or  anticoagulation  effects,  
but  with  no  or  low  side  effects  [9].  Bioactive  natural  molecules  are  good  candidates  for  such 
purposes [10–12]. As known, marine organisms produce a large amount of products, often so called 
secondary  metabolites.  They  display  ecological  functions  such  as  defense  against  predators, 
competitors and herbivores, prevention of biofouling [13,14] and some of them have been reported as 
having  important  pharmacological  proprieties  [15,16],  such  as  antiviral  [17–19],  antilonomic  [20], 
antiophidic [21], cytotoxic, antituberculosis [22], anti-inflammatory, antiangiogenic, antiadhesive [23] 
and anticoagulant [24]. Moreover, a large number of sulfated polysaccharides with antithrombotic 
effects have been isolated from marine algae [23,25–28] as well as from other natural sources; such as 
from lichens [29,30] or from Passiflora nitida leaves [31]. The inhibitory mechanism of action of these 
is still under investigation, but some speculate that molecules bind directly to thrombin and factor Xa, 
antithrombin and/or heparin cofactor II [32,33]. So, the purpose of this work was to investigate the 
effect  of  extracts  from  marine  organisms  from  the  Brazilian  coast  upon  coagulation  and 
platelet aggregation. Mar. Drugs 2011, 9  
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2. Results and Discussion 
2.1. Effects on Platelet Aggregation 
The effect of extracts from algae or sponges on platelet aggregation and coagulation was studied; 
and  it  was  shown  that  both  marine  organisms  inhibited  platelet  aggregation  or  prevented  plasma 
coagulation. Firstly, the effect of algae or sponges upon platelet aggregation was evaluated and they 
did not inhibit collagen-induced platelet aggregation on platelet rich plasma (PRP) (data not shown). 
On the other hand, the extracts of alga Dc-H (Figure 1A) or the sponges Ch and Pc (Figure 1B), 
inhibited the aggregation induced by ADP around 20%. ADP and collagen bind to different receptors 
in platelet membrane and trigger platelet aggregation by different intracellular pathways [34,35]; and 
this fact may explain why algae or sponges inhibited only the ADP-induced aggregation, but not the 
collagen one. The extracts of algae or sponges did not induce aggregation on PRP (data not shown). 
Figure 1. Effect of algae or sponges on platelet aggregation: Platelet rich plasma (PRP) 
was preincubated with dimethylsulfoxide (DMSO) (0.9% v/v, final concentration) extracts 
of algae (Panel A) or sponges (Panel B) for 2 min at 37 °C under stirring. Then, adenosine 
diphosphate  (ADP)  (15  µM)  was  added  to  induce  platelet  aggregation.  One  hundred 
percent  of  platelet  aggregation  was  obtained  with  supramaximal  concentrations  of  the 
agonist in presence of DMSO after 6 min. of reaction. Data are expressed as means ± SEM 
of three individual experiments (n = 2). Asterisk used when p < 0.05 compared to DMSO. 
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Then, the effect of algae or sponges upon aggregation of washed platelets (WP) was investigated 
(Figure 2). The extracts of alga Dm-H-PF and Dm-DC inhibited 30% the aggregation induced by 
thrombin (Figure 2A) and 15% induced by collagen (Figure 2B); while Dc-H inhibited aggregation Mar. Drugs 2011, 9  
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around 85% (Figure 2A) and 60% (Figure 2B). Dc-AC inhibited 20% and 35% aggregation induced by 
thrombin (Figure 2A) or collagen (Figure 2B), respectively. In fact, a more marked inhibitory effect on 
aggregation  induced  by  thrombin  or  collagen  could  be  observed  for  the  extract  of  alga  Dc-H 
(Figure 2A,B). Differences in the inhibitory profile may be explained by the fact that thrombin and 
collagen do not share the same receptors [36]. The experiments above were performed by incubating 
extracts of algae or sponges for 2 min with platelets. But when the algae Dc-H, Dm-H-PF, Dc-AC and 
Dm-DC were incubated with WP for 10 min, the inhibitory effect of them on platelet aggregation 
induced  by  collagen  or  thrombin  was  doubled  (data  not  shown).  The  extracts  of  Dm-H-SP  and  
Dm-Ac-PF  did  not  inhibit  aggregation  of  WP  induced  by  thrombin  (Figure  2A)  or  collagen 
(Figure 2B), even with 10 min incubation (data not shown). Four of ten sponges (De, Av, Hh and Af) 
inhibited aggregation of WP induced by thrombin (Figure 2C) or collagen (Figure 2D) after 2 min of 
incubation. Curiously, a 10% reduction on the inhibitory effect was observed when the sponges De, Hh 
or Af were incubated with platelets for 10 min (data not shown). The other two sponges (Pc, Av) did 
not inhibit aggregation either at 2 min or 10 min incubation. The extract of Pc did not interfere with 
platelet aggregation induced by both agonists (Figures 2C,D).  
Figure 2. Effects of algae or sponges on washed platelet aggregation. The extracts of algae 
(50 µg/mL) or sponges (100 µg/mL) were preincubated with WP for 2 min at 37 °C under 
stirring, and then 0.4 U/mL thrombin (Panel A, C) or 16 µg/mL collagen (Panel B, D) was 
added to induce aggregation. One hundred percent of platelet aggregation was obtained 
with supramaximal concentrations of the agonists in presence of DMSO (0.9% v/v, final 
concentration)  after  6  min  of  reaction.  Data  are  expressed  as  means  ±  SEM  of  three 
individual experiments (n = 2). Asterisk used when p < 0.05 compared to DMSO. 
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Figure 2. Cont. 
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Regardless of the extract of sponge tested, a similar inhibitory pattern (from 50% to 80%) was 
observed  for  collagen  or  thrombin.  As  seen,  most  of  algae  and  sponges  did  not  inhibit  platelet 
aggregation on PRP (Figure 1), in contrast to a pronounced inhibitory effect on WP (Figure 2). These 
results may suggest that blood plasma may somehow interfere in the inhibitory effect of extracts. 
Although the extracts inhibit platelet aggregation, they were not able to prevent shape-change which is 
at  an  early  stage  of  platelet  activation  (data  not  shown).  This  dichotomy  can  be  explained,  since 
different receptors are involved in both processes. As known from literature, sugar rich-molecules can 
inhibit platelet aggregation [37–39]. However, none of the extracts from algae or sponges inhibited 
ristocetin-induced aggregation, except for alga Dc-H in which a 20% inhibition was observed (data not 
shown).  So,  the  mechanism  of  action  extracts  seemed  not  to  be  the  same  as  the  sugars-enriched 
molecules. The inhibitory  effect on aggregation of Dc-H, differed from other extracts of algae or 
sponges as it was concentration-dependent with an Inhibitory Concentration (IC50) of 56 µg/mL for 
collagen and 47 µg/mL for thrombin (data not shown). Surprisingly, the extracts of Ma, Da, Ti, Ch and 
Pj induced aggregation only when challenged with WP (data not shown), even though they have not 
induced aggregation on PRP. This result clearly shows the interference of plasma components in the 
extract-platelet interactions, since somehow molecules in plasma would bind to sponges’ metabolites, 
preventing them from inducing aggregation; this was the case of PRP. The proaggregating mechanism 
of action is still under investigation. 
2.2. Effects on Coagulation 
A large number of bioactive molecules with anticoagulant activity have been described in marine 
organisms.  These  molecules  are  regularly  produced  from  their  primary  or  secondary  metabolism, 
including polysaccharides [28] or diterpenes [8,21]. So, the influence of the extracts of algae (Table 1) Mar. Drugs 2011, 9  
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or sponges (Table 2) on coagulation was evaluated using four in vitro methods: (1) the recalcification 
time  (RT);  (2)  prothrombin  time  (PT);  (3)  activated  partial  thromboplastin  time  (aPTT);  and  
(4)  fibrinogen  clotting  (FC).  None  of  the  extracts  from  algae  or  sponges  exerted  a  pro-coagulant 
activity (data not shown). However, most of them inhibited coagulation, but with different potencies. 
The extracts of algae did not delay coagulation on the recalcification test at 5 or 10 min of incubation, 
but  Dm-AC-PF  and  Dc-AC  did  delay  PT  and  aPTT  times,  respectively  (Table  1).  The  in vitro 
anticoagulant effect of such algae suggests that the former may have molecules that act in the extrinsic 
pathway (initiation) of the coagulation system, while the latter acts in the intrinsic one (augmentation). 
The higher anticoagulant effect of algae was observed upon fibrinogen clotting elicited by thrombin 
(Table 1). It is well known that thrombin generates fibrin through cleavage fibrinogen and induces 
platelet aggregation, and these two effects are mediated by two distinct sites, a catalytic site and a 
pharmacological one. So, we may speculate that algae extracts could also inhibit the enzymatic activity 
of thrombin. To test it, we evaluated the ability of algae to inhibit hydrolysis of S-2238 that is a 
specific  substrate  for  thrombin.  However,  none  of  the  extracts  prevented  hydrolysis  by  thrombin  
(data  not  shown);  suggesting  that  the  anticlotting  effect  of  algae  upon  fibrinogen  might  not  be 
associated with thrombin activity or that algae do not bind to the catalytic site of thrombin. 
Table  1.  Effect  of  algae  extracts  on  clotting  times.  For  RT,  the  extracts  of  algae 
(50 µg/mL)  were  preincubated  with  plasma  and  then  CaCl2  was  added  to  trigger 
coagulation.  For  PT,  extracts  (100  µg/mL)  were  incubated  with  plasma  and  then 
thromboplastin was added to induce coagulation. For aPTT, extracts (100 µL/mL) were 
incubated with plasma plus cephalin then CaCl2 was added to trigger coagulation. For FC, 
extracts (100 µg/mL) were incubated with fibrinogen and then thrombin (1 U/mL) was 
added to induce coagulation. Results are expressed as means ± SEM of two individual 
experiments (n = 4). Asterisk used when p < 0.05 compared to NaCl or DMSO (1% v/v). 
See Table 3 for species names. 
Samples 
Clotting times (s) 
RT  PT  aPTT  FC 
NaCl  122.8 ± 16  21.7 ± 0.3  32.1 ± 1.2  26.4 ± 0.5 
DMSO  149.7 ± 3.3  25.6 ± 0.2  38.8 ± 0.8  34.1 ± 1.4 
Dm-H-PF  158.3 ± 11  24.5 ± 0.2  38.7 ± 2.0  46.8 ± 1.3 * 
Dm-H-SP  156.2 ± 8.3  25.1 ± 0.4  39.3 ± 1.3  47.3 ± 1.6 * 
Dm-AC-PF  172.3 ± 13  29.9 ± 0.6 *  40.5 ± 1.1  86.4 ± 2.6 * 
Dm-AC-SP  155.6 ± 3.2  24.7 ± 1.0  39.1 ± 0.7  65.3 ± 3.5 * 
Dm-DC  171.6 ± 14  23.3 ± 0.2  40.2 ± 0.5  66.7 ± 0.8 * 
Dc-H  177.4 ± 13  27.3 ± 0.2  38.7 ± 2.4  42.7 ± 0.9 * 
Dc-AC  166.1 ± 4.1  28.9 ± 0.2  46.1 ± 2.5 *  78.4 ± 11 * 
Moreover, the extracts of sponges also inhibited clotting (Table 2). It seems that sponges were more 
effective than algae, since they inhibited coagulation in the four methods (Table 2). The extracts of Ti, 
Ch and Pj doubled coagulation time in each of the four methods; but, Ti was the most effective. Only 
the extracts of sponges Da, De and Hh did not delay coagulation in the recalcification test (Table 2). 
As in the algae tests, the extracts of sponges did not inhibit hydrolysis of S-2238 (data not shown). Mar. Drugs 2011, 9  
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Table 2. Effect of the extracted sponges on clotting time. For RT, the extracts (50 µg/mL) 
were preincubated with plasma and then CaCl2 was added to trigger coagulation. For PT, 
extracts (100 µg/mL) were incubated with plasma and then thromboplastin was added to 
induce coagulation. For aPTT, the extracts (100 µL/mL) were incubated with plasma plus 
cephalin then CaCl2 was added to trigger coagulation. For FC, the extracts (100 µg/mL) 
were  incubated  with  fibrinogen  and  then  thrombin  (1.0  U/mL)  was  added  to  induce 
coagulation. Results are expressed as means ± SEM of two individual experiments (n = 4). 
Asterisk used when p < 0.05 compared to NaCl or DMSO (1% v/v).  See Table 4  for 
species names. 
Samples 
Clotting times (s) 
RT  PT  aPTT  FC 
NaCl  124.3 ± 7.2  21.7 ± 0.3  32.1 ± 1.2  25.2 ± 0.1 
DMSO  160.6 ± 11.5  22.7 ± 0.2  34.8 ± 1.3  34.4 ± 0.4 
Pc  203.5 ± 4.7 *  27.4 ± 1.0 *  48.5 ± 1.4 *  86.6 ± 5.8 * 
Ma  227.0 ± 8.0 *  27.1 ± 0.7 *  54.8 ± 2.0 *  99.8 ± 9.6 * 
Da  210.6 ± 17.1  27.9 ± 1.2 *  52.3 ± 1.7 *  88.9 ± 6.9 * 
De  197.2 ± 10.6  26.3 ± 0.4 *  54.1 ± 1.2 *  101.6 ± 6.0 * 
Ti  246.0 ± 9.3 *  27.3 ± 0.8 *  64.2 ± 1.7 *  176.2 ± 4.7 * 
Av  239.3 ± 14.8 *  27.1 ± 0.6 *  58.0 ± 1.6 *  94.4 ± 5.4 * 
Hh  185.6 ± 10.1  23.9 ± 0.6  40.6 ± 1.1 *  76.6 ± 3.1 * 
Af  234.6 ± 13.6 *  25.7 ± 0.5 *  45.2 ± 2.2 *  75.9 ± 5.4 * 
Ch  296.3 ± 29.0 *  27.5 ± 0.4 *  53.2 ± 2.8 *  92.6 ± 8.1 * 
Pj  278.6 ± 6.5 *  26.3 ± 0.5 *  52.2 ± 1.0 *  107.1 ± 5.0 * 
Table 3. Extracts of algae studied with their solvent, collection site, voucher specimen and code. 
Algae  Solvent  Collection Site  Voucher  Code 
Dictyota  
menstrualis  Ethyl Acetate 
Arquipélago de São 
Pedro e São Paulo, RN 
(00°55′N–29°21′W) 
11006  Dm-AC-SP 
Dictyota  
menstrualis  Ethyl Acetate 
Praia do Forno 
Armação de Búzios, RJ 
(22°45′S–41°52′W) 
84815  Dm-AC-PF 
Dictyota  
menstrualis  Hexane 
Arquipélago de São 
Pedro e São Paulo, RN 
(00°55′N–29°21′W) 
11006  Dm-H-SP 
Dictyota  
menstrualis  Hexane 
Praia do Forno 
Armação de Búzios, RJ 
(22°45′S–41°52′W) 
84815  Dm-H-PF 
Dictyota  
menstrualis  Dichloromethane 
Praia Rasa 
Armação de Búzios, RJ 
(22°45′S–41°52′W) 
10017  Dm-DC 
Dictyota  
ciliolata  Hexane 
Praia Vermelha 
Angra dos Reis, RJ 
(23°00′S–44°19′W) 
10415  Dc-H 
Dictyota  
ciliolata  Ethyl Acetate 
Praia Vermelha 
Angra dos Reis, RJ 
(23°00′S–44°19′W) 
10415  Dc-AC Mar. Drugs 2011, 9  
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Table 4. Extracts of sponges studied with their solvent, collection site, voucher specimen 
and code. 
Sponge  Solvent  Collection Site  Voucher  Code 
Petromica  
citrina 
Dichloromethane 
Arquipélago das Cagarras 
Rio de Janeiro, RJ 
(23°01′S–43°13′W) 
14537  Pc 
Mycale  
angulosa 
Acetone 
Praia da Baleia 
Angra dos Reis, RJ 
(23°01′S–44°14′W) 
14529  Ma 
Chondrosia sp.  Acetone 
Praia da Baleia 
Angra dos Reis, RJ 
(23°01′S–44°14′W) 
14551  Ch 
Dysidea  
etherea 
Acetone 
Praia da Baleia 
Angra dos Reis, RJ 
(23°01′S–44°14′W) 
14525  De 
Desmapsamma 
anchorata 
Acetone 
Ilha do Bonfim 
Angra dos Reis, RJ 
(23°01′S–44°19′W) 
14520  Da 
Amphimedon  
viridis 
Acetone 
Ilha do Bonfim. 
Angra dos Reis, RJ 
(23°01′S–44°19′W) 
14517  Av 
Tedania ignis  Acetone 
Praia de Tarituba 
Paraty, RJ 
(23°02′S–44°35′W) 
14522  Ti 
Hymeniacidon 
heliophila 
Acetone 
Praia de Itaipu 
Niterói, RJ 
(22°58′S–43°02′W) 
14528  Hh 
Aplysina  
fulva 
Acetone 
Praia do Forno 
Arraial do Cabo, RJ 
(22°57′S–42°00′W) 
13554  Af 
Polymastia 
janeirensis 
Acetone 
Praia do Forno 
Arraial do Cabo, RJ 
(22°57′S–42°00′W) 
14512  Pj 
Concerning the extracts of algae, the collection site and the type of extract may have influenced the 
results, mainly because of the geographical variation of each species and the chemical composition of 
extracts. It is worthwhile to mention that the polarity of solvents may also influence the potency of 
some pharmacological effects, since different molecules can be extracted [40]. The extracts evaluated 
in this work contain nonpolar molecules, such as diterpenes, fatty acids or sterols. As can be seen, the 
extracts of D. menstrualis prepared in ethyl acetate from Búzios (Dm-AC-PF) and D. ciliolata in 
hexane from Angra dos Reis (Dc-H) presented the most expressive anticoagulant activity. The extract 
of Ti had the best anticoagulant effect among sponges. Mar. Drugs 2011, 9  
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3. Experimental Section 
3.1. Material 
Collagen (Type I), ristocetin and adenosine diphosphate (ADP) were purchased from Chrono Log 
Corporation, dimethylsulfoxide (DMSO) and human thrombin from Merck. Chromogenic substrate,  
H-D-Phe-pipecolyl-Arg-pNA.2HCl (S-2238) came from Chromogenix. All the others reagents were of 
the best grade available. 
3.2. Marine Organisms 
The air-dried algae (Table 3) and the frozen-dried sponge (Table 4) were collected in regions of 
Brazilian coast by free or scuba diving and extracted three times with appropriate solvent at room 
temperature (25 °C) for 24 h (Tables 3 and 4). After filtration, the solvent was evaporated under 
reduced pressure, yielding a crude residue. An aliquot of each extract was weighted, aliquoted and 
frozen. The extracts were dissolved in DMSO in order to perform the biological assays, and right after 
assays,  extracts  were  stored  at  4  °C.  A  voucher  specimen  of  each  sponge  has  been  deposited  at 
National Museum of the Federal University of Rio de Janeiro (MN-UFRJ), Rio de Janeiro, Brazil. 
Each species of algae was deposited at the Herbarium of State University of Rio de Janeiro (UERJ), 
RJ, Brazil and authenticated by Dr. Joel Campos de Paula (UNIRIO). The experimental procedures 
employed here removed sugar, lipids and proteins, and extracted less polar components and nonpolar 
ones, as diterpenes, fatty acids and sterols. 
3.3. Platelet Aggregation Assays 
The procedure described by [41] was employed with some modifications. Platelet aggregation was 
measured turbidimetrically in an Aggregometer (Chrono Log model 490 2D, Havertown, USA) using 
Platelet-Rich-Plasma (PRP) or Washed-Platelets (WP). PRP (collected in citrate 0.38% w/v) and WP 
(collected  in  5  mM  EDTA)  were  obtained  from  whole  blood  of  healthy  volunteer  donators  and 
centrifuged at 380× g for 12 min at room temperature. The extracts of either algae or sponges were 
incubated with 250 µL PRP or WP for 2 min at 37 °C under stirring, and then platelet aggregation was 
triggered by adding platelet agonists (collagen, ADP, ristocentin or thrombin). Assays were performed 
at  37  °C  in  siliconized  glass  cuvettes  with  a  total  volume  of  300  µL.  Control  experiments  were 
performed  using  platelet  agonists  in  the  presence  or  in  the  absence  of  DMSO  (0.9%  v/v,  final 
concentration).  One  hundred  percent  (100%)  of  aggregation  was  obtained  with  a  supra  maximal 
concentration of agonists 6 min after the addition of agonist, whilst 0% of aggregation was the light 
transmittance of PRP or WP alone (base line). The Inhibitory Concentration (IC50) was determined as 
the amount of extract (µg/mL) able to inhibit 50% of platelet aggregation induced by agonists. 
3.4. Clotting Assays 
Four in vitro clotting assays were performed using a Multichannel Coagulometer (Amelung, model 
KC4A), as listed below. Mar. Drugs 2011, 9  
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Recalcification Time (RT): The extracts of algae or sponges were incubated with 200 µL of a pool 
of normal human plasma (collected in citrate 3.8% v/v) for 10 min at 37 °C. Then, CaCl2 (12.5 mM 
final concentration) was added to the mixture and clotting time recorded. 
Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) tests: Both assays were 
performed according to the manufacturer instructions (Soluplastin and aPTTest elagic acid, Wiener 
lab). For PT assays, extracts were incubated with 50 µL of human plasma during 5 min at 37 °C and 
then 100 µL of pre-warmed thromboplastin with calcium were added to the mixture to start clotting. 
For aPTT assay, extracts were mixed with 100 µL of human plasma and 100 µL of aPTT reagent 
cephalin plus kaolin for 5 min at 37 °C. The reaction was started by the addition of CaCl2 (12.5 mM, 
final concentration).  
Fibrinogen clotting (FC): The extracts of algae and sponges were incubated for 10 min at 37 °C 
with  200  µL  of  commercial  fibrinogen  (2  mg/mL,  final  concentration).  After  this,  clotting  was 
triggered by adding thrombin (1.0 U/mL). 
3.5. Hydrolytic Activity upon Chromogenic Assay 
The  hydrolysis  of  the  chromogenic  substrate  S-2238  (used  for  thrombin-like  enzymes)  was 
monitored by using a Thermomax Microplate reader (Molecular Devices, Menlo Park, CA, USA). The 
extracts of algae or sponges were incubated for 10 min at 37 °C, and then reaction was triggered by 
adding S-2238 (0.1 mM, final concentration). The reaction was monitored at A405nm during 20 min  
at 37 °C. Positive control experiments were performing by adding thrombin (1.0 U/mL), instead of  
marine organisms. 
3.6. Statistical Analyses 
The results were expressed as means ± standard error (SEM) obtained with an indicated number of 
experiments  performed.  The  statistical  significance  of  differences  among  experimental  groups  and 
control groups were evaluated using Student t test with p value <0.05. 
4. Conclusions 
In this work, we screened extracts from Brazilian algae and sponges having the capacity to interfere 
with  platelet  aggregation  and  coagulation  and,  thereby,  observed  that  some  extracts  inhibited 
coagulation and platelet aggregation. Further chemical work should be done to identify which specific 
bioactive  principle  in  algae  or  sponges  is  responsible  for  the  anticoagulant  effect  and  also  to 
understand the structure-function relationship involved in such phenomena. Moreover, this work also 
shows the importance of bioprospecting studies with the rich marine biodiversity along the Brazilian 
coast, looking for natural compounds with pharmacological properties or biotechnological potential 
which could be used in the development of new clinical drugs. Up to now, it is very difficult to address 
advantages  of  algae  or  sponges  over  existing  anticoagulant  therapies  or  their  role  in  thrombotic 
processes. However, we can infer some favorable points that are worth further studying and looking 
for molecules from marine organisms with an anticoagulant effect: (1) actually, there is more interest 
in  developing  therapeutic  agents  from  a  non-mammalian  source  in  order  to  diminish  side  effects  Mar. Drugs 2011, 9  
 
 
1356 
(such as hemorrhage), risk of contamination with foreign bodies or pathogenic substances; (2) marine 
products could also be useful to help to design new structure-based anticoagulant drugs. 
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